The
Endocrine Society wants to keep you up to date on the latest developments relevant to your research and practice. Below are important dates we're tracking on the congressional calendar, as well as funding opportunities, announcements and initiatives from various federal agencies.
Advocacy – Important Dates
November:
- Nov. 3 – Election day
- Nov. 9 – Senate returns from recess
- Nov. 16 - House returns from recess
- Nov. 17 – Endocrine Society launches new campaign to urge Congress to renew Special Diabetes Program and fund the National Institutes of Health
- Nov. 23-27 – Thanksgiving Recess
December:
- Dec. 11 – End of Continuing Resolution (fiscal cliff) and Special Diabetes Program funding
- Dec. 10 – House goes on recess
- Dec. 14 – The electors (members of the electoral college) meet in their respective state capitals and DC to formally vote for the president and vice president
- Dec. 17 – Endocrine Society hosts Physician Payment webinar (still waiting on registration link)
- Dec. 18 – Senate goes on recess
Funding Opportunities & Announcements
+ All Researchers
- Due Dec. 4: NCI reissued its Research Specialist Award (R50). The funding opportunity announcements (FOAs) are targeted to non-tenure track laboratory, core, and data scientists whose salary is currently supported by NCI-funded principal investigators’ grants. Learn more about these opportunities. Letters of Intent are due Dec. 4, 2020.
- Deadline Dec. 11: Action Alert – Urge Congress to Reauthorize SDP & Fund NIH. It is critical that all members of Congress hear from YOU, their constituents, about the need to reauthorize SDP and the importance of supplemental funding for biomedical research. Learn more and take action today.
- Due Feb. 19, 2021: NIH issued an FOA on Nov. 4 to promote innovative research to enhance the utility and usability of selected Common Fund data sets. Applications are due February 19, 2021. Learn more at the NIH Grants Guide.
- Effective Jan. 25, 2023: NIH has released its final NIH Policy for Data Management and Sharing (DMS Policy) to promote the management and sharing of scientific data generated from NIH-funded or conducted research. The policy, which becomes effective Jan. 25, 2023, was discussed in a recent blog post from the NIH Office of Science Policy.
+ Basic and Clinical Research
- Due Jan. 24, 2021: NIH is accepting applications for the FY 2021 Sexual & Gender Minority (SGM) Administrative Supplements program. This Notice of Special Interest announces the availability of administrative supplements to provide funding for the expansion of existing research projects to incorporate SGM populations, which include, but are not limited to, those populations described in Notice NOT-OD-19-139. Applications are due Jan. 25, 2021 by 5PM local time of applicant organization. Read full Notice.
- Deadlines: April 2021: NIH has issued a series of notices announcing their intention to publish several funding opportunities for the NIH Common Fund Nutrition for Precision Health, powered by the All of Us Research Program. The goal of the Nutrition for Precision Health program is to develop algorithms that predict individual responses to foods and dietary patterns. See the notices on the NIH Grants Guide.
- strong style="font-size: 1.25rem;">Due dates: April 2021: NIH and Academy of Finland (AKA) has established a partnership program that seeks to encourage increased collaborative research between investigators in the U.S. and Finland. This is to be facilitated through the submission of grant applications from U.S. institutions that include collaboration with Finnish investigators selected by AKA to participate in the joint research program. Learn more.
+ Clinical Research
- Issued Oct. 23: NIH released guidance to the extramural research community regarding NIH implementation the HHS Office for Human Research Protections (OHRP)’s determination of Exception to the Single IRB Review Requirements for certain research activities during the COVID-19 Public Health Emergency. As long as the OHRP's determination is in place, NIH will not require use of a single IRB for NIH-funded research that qualifies for an exception as outlined in the OHRP COVID-19 Exception Determination.
- Issued Nov. 10: NIH Director Dr. Francis Collins urged clinical researchers involved in COVID-19 or SARS-CoV-2 clinical trials to share data as swiftly as possible on ClinicalTrials.gov. NIH is prioritizing these submissions to make information available more rapidly, and is taking other steps to expedite sharing COVID-19 clinical trial results. Read the NIH Director's statement.
+ Clinical Science and Clinical Practice
- Upcoming: Be prepared to administer the COVID-19 vaccine when it’s available. Read the enrollment section of CMS’s COVID-19 provider toolkit to see if you need to take action now to be ready. Call your Medicare Administrative Contractor (MAC)-specific enrollment hotline (PDF) to give your valid legal business name, national provider identifier, tax identification number, practice location, and state license, if applicable.
- Coverage started Nov. 10: Medicare beneficiaries are covered for monoclonal antibody infusions (bamlanivimab) to treat COVID-19 with no cost-sharing during the Public Health Emergency. Bamlanivimab received an Emergency Use Authorization from the FDA on Nov 9. CMS anticipates that this monoclonal antibody product will initially be given to health care providers at no charge. Medicare will not pay for the monoclonal antibody products that providers receive for free but this action provides for reimbursement for the infusion of the product. Learn more at Monoclonal Antibody COVID-19 Infusion Program Instruction.
